Response to Letter to the Editor Navigating the challenge of patient selection and scales to measure outcomes in ketamine trials for treatment-resistant depression.

IF 4.5 3区医学 Q1 CLINICAL NEUROLOGY

Journal of Psychopharmacology Pub Date : 2024-09-12 DOI:10.1177/02698811241276505

Paul Glue, Neil McNaughton

引用次数: 0

Abstract

The letter about the article "Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study" that discusses some points about methodology, outcome measures, and results.

查看原文本刊更多论文

回应致编辑的信在氯胺酮治疗难治性抑郁症的试验中，如何选择患者和测量结果的量表是一项挑战。

关于 "氯胺酮治疗难治性重度抑郁症：双盲主动对照交叉研究 "一文的信件，其中讨论了有关方法、结果测量和结果的一些要点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Psychopharmacology 医学-精神病学

CiteScore

8.60

自引率

4.90%

发文量

126

审稿时长

3-8 weeks

期刊介绍： The Journal of Psychopharmacology is a fully peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of psychopharmacology. The journal provides an essential forum for researchers and practicing clinicians on the effects of drugs on animal and human behavior, and the mechanisms underlying these effects. The Journal of Psychopharmacology is truly international in scope and readership.